CKD
MCID: CHR684
MIFTS: 66

Chronic Kidney Disease (CKD)

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases

Aliases & Classifications for Chronic Kidney Disease

MalaCards integrated aliases for Chronic Kidney Disease:

Name: Chronic Kidney Disease 12 29 6 42 3 15 37 62 17 32
Chronic Renal Disease 12 15
Ckd 12 3
Chronic Renal Failure Syndrome 12
Renal Failure - Chronic 12
Kidney Failure, Chronic 43
Chronic Kidney Failure 12
Chronic Renal Failure 74
Renal Failure Chronic 54
Crf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:784
ICD9CM 34 585.6
MeSH 43 D007676
NCIt 49 C9438
SNOMED-CT 67 46177005 90688005
ICD10 32 N18 N18.9
UMLS 71 C0022661

Summaries for Chronic Kidney Disease

MedlinePlus : 42 You have two kidneys, each about the size of your fist. Their main job is to filter your blood. They remove wastes and extra water, which become urine. They also keep the body's chemicals balanced, help control blood pressure, and make hormones. Chronic kidney disease (CKD) means that your kidneys are damaged and can't filter blood as they should. This damage can cause wastes to build up in your body. It can also cause other problems that can harm your health. Diabetes and high blood pressure are the most common causes of CKD. The kidney damage occurs slowly over many years. Many people don't have any symptoms until their kidney disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. Treatments cannot cure kidney disease, but they may slow kidney disease. They include medicines to lower blood pressure, control blood sugar, and lower cholesterol. CKD may still get worse over time. Sometimes it can lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplantation. You can take steps to keep your kidneys healthier longer: Choose foods with less salt (sodium) Control your blood pressure; your health care provider can tell you what your blood pressure should be Keep your blood sugar in the target range, if you have diabetes Limit the amount of alcohol you drink Choose foods that are healthy for your heart: fruits, vegetables, whole grains, and low-fat dairy foods Lose weight if you are overweight Be physically active Don't smoke NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Chronic Kidney Disease, also known as chronic renal disease, is related to end stage renal failure and renal osteodystrophy. An important gene associated with Chronic Kidney Disease is PKD2 (Polycystin 2, Transient Receptor Potential Cation Channel), and among its related pathways/superpathways are p70S6K Signaling and PI3K-Akt signaling pathway. The drugs Nitric Oxide and Nifedipine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are cardiovascular system and homeostasis/metabolism

CDC : 3 CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.

PubMed Health : 62 About chronic kidney disease: Our kidneys are vital organs that clean our blood and affect many different bodily functions. Various medical conditions can cause the kidneys to stop working properly for a short time – for example, if blood isn’t pumped around the body properly or if an enlarged prostate or kidney stones make urine build up in the kidneys. But if the kidneys still aren’t working at full capacity more than three months later or are permanently damaged, then the problem is considered to be chronic kidney disease. The most common causes in adults are diabetes and high blood pressure. Older people are especially prone to developing chronic kidney disease. It often goes unnoticed for a long time because poorly functioning kidneys don’t cause any problems at first. Treatment mostly aims to stop the kidney disease from getting worse, or at least delay the process. It is also important to treat complications such as anemia, acidosis or changes in bone metabolism. If the kidneys fail completely, dialysis or a kidney transplant can prolong the person’s life.

Wikipedia : 74 Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney... more...

Related Diseases for Chronic Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease Ren-Related Kidney Disease

Diseases related to Chronic Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1564)
# Related Disease Score Top Affiliating Genes
1 end stage renal failure 34.6 UMOD REN PTH NPHS2 IL6 EPO
2 renal osteodystrophy 34.5 PTH FGF23 EPO CASR
3 secondary hyperparathyroidism 34.0 PTH FGF23 EPO CASR ALB
4 gout 33.7 UMOD INS IL6 ALB
5 kidney disease 33.7 UMOD RNLS REN PTH PKD2 NPHS2
6 autosomal dominant tubulointerstitial kidney disease 33.6 UMOD REN
7 calciphylaxis 33.6 PTH FGF23 EPO CASR ALB
8 hypokalemia 33.4 REN INS CASR ALB ACE
9 cystic kidney disease 33.3 UMOD REN PTH PKD2 MKS1 EPO
10 hypoparathyroidism 33.2 PTH FGF23 CASR
11 hyperparathyroidism 33.0 PTH FGF23 EPO CASR ALB
12 diabetes mellitus 32.9 UMOD TUG1 REN PTH INS IL6
13 hyperphosphatemia 32.8 PTH FGF23 CRP CASR ALB
14 autosomal dominant tubulointerstitial kidney disease, ren-related 32.8 UMOD REN
15 pierson syndrome 32.8 NPHS2 COL4A5 COL4A4
16 deficiency anemia 32.8 PTH INS IL6 FGF23 EPO CST3
17 renal tubular dysgenesis 32.8 REN AGTR1 ACE
18 lipid metabolism disorder 32.7 INS IL6 CRP ACE
19 microvascular complications of diabetes 3 32.7 REN INS ALB AGTR1 ACE
20 bone disease 32.7 PTH IL6 FGF23 EPO CASR
21 uremia 32.6 REN PTH INS IL6 EPO CRP
22 rickets 32.6 PTH FGF23 CASR ALB
23 vascular disease 32.6 REN PTH INS IL6 EPO CST3
24 congestive heart failure 32.6 REN INS IL6 EPO CRP ALB
25 metabolic acidosis 32.6 PTH IL6 FGF23 ALB
26 hyperuricemia 32.5 UMOD REN PTH INS CRP ALB
27 peripheral vascular disease 32.5 INS IL6 EPO CRP ALB ACE
28 coronary artery anomaly 32.5 IL6 CRP ALB AGTR1 ACE
29 atrial fibrillation 32.5 REN INS IL6 CRP ALB AGTR1
30 arteries, anomalies of 32.4 REN INS IL6 CRP ALB AGTR1
31 glomerulonephritis 32.4 NPHS2 COL4A5 COL4A4 ALB AGTR1 ACE
32 heart disease 32.4 REN INS IL6 EPO CST3 CRP
33 polycystic kidney disease 32.3 REN PKD2 FGF23 EPO CST3 ALB
34 sleep apnea 32.2 REN INS IL6 EPO CRP ALB
35 coronary heart disease 1 32.2 INS IL6 CRP AGTR1 ACE
36 cerebrovascular disease 32.2 REN INS IL6 CRP AGTR1 ACE
37 osteoporosis 32.2 PTH INS IL6 FGF23 CST3 CRP
38 acute kidney failure 32.2 UMOD REN CST3 ALB
39 arteriosclerosis 32.2 INS IL6 CST3 CRP ACE
40 iron deficiency anemia 32.2 IL6 FGF23 EPO CRP
41 peripheral artery disease 32.2 IL6 CST3 CRP ACE
42 bone resorption disease 32.2 PTH INS IL6 FGF23 CRP CASR
43 fatty liver disease 32.1 INS IL6 CRP ALB
44 hypothyroidism 32.1 REN INS CST3 CRP ALB ACE
45 hypercholesterolemia, familial, 1 32.1 INS CRP ACE
46 hypertensive nephropathy 32.1 CST3 ALB AGTR1 ACE
47 acute cystitis 32.1 UMOD REN INS IL6 CRP ALB
48 sleep disorder 32.1 REN INS IL6 CRP ACE
49 intermediate coronary syndrome 32.0 REN INS IL6 CRP ALB ACE
50 interstitial nephritis 32.0 UMOD REN CRP ALB AGTR1 ACE

Graphical network of the top 20 diseases related to Chronic Kidney Disease:



Diseases related to Chronic Kidney Disease

Symptoms & Phenotypes for Chronic Kidney Disease

MGI Mouse Phenotypes related to Chronic Kidney Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ACE AGTR1 ALB COL4A5 CRP CST3
2 homeostasis/metabolism MP:0005376 10.21 ACE AGTR1 ALB CASR COL4A4 COL4A5
3 growth/size/body region MP:0005378 10.18 ACE AGTR1 CASR COL4A4 FGF23 IL6
4 endocrine/exocrine gland MP:0005379 10.1 ACE ALB CASR CST3 FGF23 IL6
5 hematopoietic system MP:0005397 10.1 ACE AGTR1 CASR COL4A5 EPO FGF23
6 immune system MP:0005387 10.06 ACE AGTR1 ALB CASR COL4A4 COL4A5
7 digestive/alimentary MP:0005381 10.03 ALB CASR COL4A4 FGF23 IL6 INS
8 mortality/aging MP:0010768 9.86 ACE AGTR1 ALB CASR COL4A4 COL4A5
9 renal/urinary system MP:0005367 9.47 ACE AGTR1 ALB CASR COL4A4 COL4A5

Drugs & Therapeutics for Chronic Kidney Disease

PubMed Health treatment related to Chronic Kidney Disease: 62

The most suitable treatment for chronic kidney disease will depend on the cause and stage of the disease, as well as on the person’s life circumstances and preferences. If the kidneys are still working at a nearly normal level, treatment should aim to stop or slow down the progression of the disease. This is mainly done using medication to lower blood pressure levels and prevent cardiovascular disease . If you have diabetes , it's important to regulate your blood sugar levels. If complications such as anemia or bone metabolism disorders have already occurred, then more medications are used – such as medicines that contain iron or stimulate the production of blood , as well as medications called “phosphate binders.” If there is too much acid in your body, bicarbonates are used. In addition to the medication, the treatment will include a diet suited to the stage of the disease, drinking the right amounts of liquids and physical exercise . Dialysis or a kidney transplant are considered if the kidneys fail completely. In the vast majority of people with complete kidney failure , at least one of these options is possible. Some people make a conscious decision not to use either, accepting the fact that they could die soon afterwards. Palliative treatment may then be suitable for them – enabling a final phase of life that is as pleasant as possible.

Drugs for Chronic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 829)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Nifedipine Approved Phase 4 21829-25-4 4485
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4
Fosinopril Approved Phase 4 98048-97-6 55891
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
8
Enoxaparin Approved Phase 4 9005-49-6 772
9
Digoxin Approved Phase 4 20830-75-5 30322 2724385
10
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
11
Indapamide Approved Phase 4 26807-65-8 3702
12
Methyldopa Approved Phase 4 555-30-6 38853
13
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
14
Capsaicin Approved Phase 4 404-86-4 1548943
15
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
16
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
17
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
18
Cinacalcet Approved Phase 4 226256-56-0 156419
19
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
20
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
21
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
22
Telavancin Approved Phase 4 372151-71-8
23
Zidovudine Approved Phase 4 30516-87-1 35370
24
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
25
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
26
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
27
Ramipril Approved Phase 4 87333-19-5 5362129
28
Dalteparin Approved Phase 4 9005-49-6
29
Deflazacort Approved, Investigational Phase 4 14484-47-0
30
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Amlodipine Approved Phase 4 88150-42-9 2162
33
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
34
Dolutegravir Approved Phase 4 1051375-16-6 54726191
35 Taurolidine Approved, Investigational Phase 4 19388-87-5
36
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
37
Colchicine Approved Phase 4 64-86-8 6167 2833
38
Iodine Approved, Investigational Phase 4 7553-56-2 807
39
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
40
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
41
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
42
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
43
Aminophylline Approved Phase 4 317-34-0 9433
44
Liraglutide Approved Phase 4 204656-20-2 44147092
45
alemtuzumab Approved, Investigational Phase 4 216503-57-0
46
Insulin glargine Approved Phase 4 160337-95-1
47
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
48
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
49
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
50
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825

Interventional clinical trials:

(show top 50) (show all 3841)
# Name Status NCT ID Phase Drugs
1 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
2 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
3 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
4 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
5 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
6 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
7 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
8 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
9 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
10 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
11 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
12 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
13 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
14 Efficacy of Vitamin D Supplementation in Obese Children Unknown status NCT02956408 Phase 4
15 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
16 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
17 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
18 Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study Unknown status NCT01631058 Phase 4 Everolimus
19 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
20 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
21 Randomized Open Clinical Trial to Compare the Effectiveness of the Administration of Diuretics in Hemodialysis Patients With Residual Renal Function in Single Centre Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
22 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
23 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
24 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
25 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
26 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
27 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
28 Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes Unknown status NCT01635387 Phase 4 aliskiren
29 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
30 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
31 Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4) Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
32 Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease Unknown status NCT00719316 Phase 4 Aliskiren
33 Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
34 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
35 Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
36 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
37 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
38 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
39 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
40 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
41 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
42 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
43 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
44 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
45 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
46 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
47 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
48 Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial. Unknown status NCT01481688 Phase 4
49 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
50 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline

Search NIH Clinical Center for Chronic Kidney Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Kidney Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: kidney failure, chronic

Genetic Tests for Chronic Kidney Disease

Genetic tests related to Chronic Kidney Disease:

# Genetic test Affiliating Genes
1 Chronic Kidney Disease 29

Anatomical Context for Chronic Kidney Disease

MalaCards organs/tissues related to Chronic Kidney Disease:

40
Kidney, Bone, Heart, Endothelial, Liver, Testes, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Kidney Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Chronic Kidney Disease

Articles related to Chronic Kidney Disease:

(show top 50) (show all 34291)
# Title Authors PMID Year
1
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 54 61
19929273 2010
2
Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. 54 61
20150846 2010
3
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. 54 61
19347366 2009
4
Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. 54 61
20025585 2009
5
[BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients]. 54 61
19947237 2009
6
Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. 54 61
19535427 2009
7
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. 54 61
19083024 2009
8
Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. 54 61
19460838 2009
9
Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. 54 61
19138652 2009
10
Insulin resistance in chronic uremia. 54 61
19121765 2009
11
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 54 61
19494617 2009
12
[Insulin resistance and chronic kidney disease]. 54 61
18514051 2008
13
Vitamin D: an old prohormone with an emergent role in chronic kidney disease. 54 61
18587719 2008
14
[Peritoneal dialysis and insulin resistance in patients with chronic kidney disease due to nondiabetic nephropathy]. 54 61
18634374 2008
15
Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure. 54 61
18923754 2008
16
Adiponectin and chronic kidney disease. 54 61
17198925 2007
17
Association between vitamin D receptor gene polymorphisms and susceptibility to chronic kidney disease and periodontitis. 54 61
17914260 2007
18
Stature in children with chronic kidney disease: analysis of NAPRTCS database. 54 61
16583244 2006
19
Arginine, arginine analogs and nitric oxide production in chronic kidney disease. 54 61
16932427 2006
20
Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. 54 61
16257266 2006
21
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. 54 61
16691036 2006
22
Biomarkers in chronic kidney disease: utility and issues towards better understanding. 54 61
16205471 2005
23
[Early diagnosis of chronic kidney diseases]. 54 61
15742164 2005
24
Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. 54 61
15585515 2005
25
Association of TGF-beta1 polymorphisms with chronic renal disease. 54 61
15593053 2004
26
Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. 54 61
15200442 2004
27
[Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease]. 54 61
15577039 2004
28
Vascular calcification in chronic kidney disease. 54 61
14730511 2004
29
Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. 54 61
15090865 2004
30
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. 54 61
14633152 2003
31
Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? 54 61
14681862 2003
32
Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. 54 61
11812876 2002
33
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. 54 61
11453706 2001
34
Urinary excretion of vasoactive substances in chronic renal failure. 54 61
11393385 2001
35
Serum hepatocyte growth factor levels in patients with chronic renal disease--effect of GFR and pathogenesis. 54 61
11768321 2001
36
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. 54 61
10739792 2000
37
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. 54 61
10219067 1999
38
The effect of metabolic acidosis on serum apolipoprotein A I and apolipoprotein B levels in children with chronic renal failure. 54 61
9413770 1997
39
Endothelial function and the kidney. An emerging target for cardiovascular therapy. 54 61
9034751 1997
40
Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients. 54 61
9071084 1996
41
The changes in serum type I and III procollagen, insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in children with chronic renal failure. 54 61
8936957 1996
42
Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. 54 61
15387752 1996
43
Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. 54 61
7604809 1995
44
Insulin and growth in chronic renal failure. 54 61
7917856 1994
45
A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. 54 61
8278382 1994
46
Effects of atrial natriuretic peptide (99-126) in chronic renal disease in man. 54 61
1831249 1991
47
Acquired long QT syndrome in chronic kidney disease patients. 61
31878817 2020
48
Prevalence and Clinical Characteristics of Asymptomatic Pyuria in Chronic Kidney Disease. 61
31858764 2020
49
Sirt6 attenuates hypoxia-induced tubular epithelial cell injury via targeting G2/M phase arrest. 61
31603249 2020
50
Chronic kidney disease and kidney stones. 61
31972597 2020

Variations for Chronic Kidney Disease

ClinVar genetic disease variations for Chronic Kidney Disease:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PKD2 NM_000297.4(PKD2):c.357_364delinsTAGGACG (p.Pro120fs)indel Pathogenic 373955 rs1057518797 4:88929242-88929249 4:88008090-88008097
2 COL4A5 NM_033380.3(COL4A5):c.3614G>T (p.Gly1205Val)SNV Pathogenic 523547 rs1556446493 X:107911558-107911558 X:108668328-108668328
3 MKS1 NM_001165927.1(MKS1):c.1085_1087del (p.Ser362del)deletion Pathogenic/Likely pathogenic 217677 rs754279998 17:56285514-56285516 17:58208153-58208155
4 SLC13A5 NM_177550.4(SLC13A5):c.231+2T>GSNV Likely pathogenic 183313 rs730882222 17:6610345-6610345 17:6707026-6707026
5 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro)SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468

Expression for Chronic Kidney Disease

Search GEO for disease gene expression data for Chronic Kidney Disease.

Pathways for Chronic Kidney Disease

GO Terms for Chronic Kidney Disease

Cellular components related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 UMOD RNLS REN PTH INS IL6
2 endoplasmic reticulum lumen GO:0005788 9.7 INS IL6 FGF23 CST3 COL4A5 COL4A4
3 extracellular space GO:0005615 9.44 RNLS REN PTH INS IL6 FGF23
4 collagen type IV trimer GO:0005587 9.26 COL4A5 COL4A4

Biological processes related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 PKD2 INS IL6 CRP CASR
2 angiotensin maturation GO:0002003 9.55 REN ACE
3 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 9.54 COL4A5 COL4A4
4 negative regulation of blood vessel diameter GO:0097756 9.52 INS CRP
5 negative regulation of lipid storage GO:0010888 9.51 IL6 CRP
6 response to fibroblast growth factor GO:0071774 9.48 PTH CASR
7 neutrophil mediated immunity GO:0002446 9.46 IL6 ACE
8 kidney development GO:0001822 9.46 REN PKD2 AGTR1 ACE
9 phosphate ion homeostasis GO:0055062 9.43 PTH FGF23
10 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.4 AGTR1 ACE
11 negative regulation of protein oligomerization GO:0032460 9.37 INS ALB
12 cellular protein metabolic process GO:0044267 9.35 INS IL6 FGF23 CST3 ALB
13 metanephric ascending thin limb development GO:0072218 9.32 UMOD PKD2
14 renin-angiotensin regulation of aldosterone production GO:0002018 9.26 REN AGTR1
15 acute-phase response GO:0006953 8.92 INS IL6 EPO CRP

Molecular functions related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 br